We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

108 hedge funds and large institutions have $572M invested in Mineralys Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 17

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $540M → $572M (+$32.2M)

4.16% more ownership

Funds ownership: 89.25% → 93.4% (+4.2%)

2% more funds holding

Funds holding: 106 → 108 (+2)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

88% less call options, than puts

Call options by funds: $1K | Put options by funds: $8K

Holders
108
Holders Change
+2
Holders Change %
+1.89%
% of All Funds
1.42%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
16
Increased
44
Reduced
17
Closed
14
Calls
$1K
Puts
$8K
Net Calls
-$7K
Net Calls Change
-$50K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$13.1M
2
IHAM
Integral Health Asset Management
New York
+$6.79M
3
JP Morgan Chase
JP Morgan Chase
New York
+$6.3M
4
SC
Stempoint Capital
New York
+$5.23M
5
Jennison Associates
Jennison Associates
New York
+$5.04M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$7.27M
2
ASP
Adams Street Partners
Illinois
-$5.27M
3
O
OrbiMed
New York
-$5.12M
4
BOCH
Blue Owl Capital Holdings
New York
-$2.38M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
CP
1
Catalys Pacific
Japan
$106M – – –
SB
2
Samsara BioCapital
California
$62.5M – – –
RCM
3
RA Capital Management
Massachusetts
$59.7M – – –
TCM
4
TCG Crossover Management
California
$30.4M – – –
BlackRock
5
BlackRock
New York
$26.3M -$73.8K -5,646 -0.3%
SOCM
6
SR One Capital Management
Pennsylvania
$24.8M – – –
Franklin Resources
7
Franklin Resources
California
$21.5M +$1.1K +84 +0%
O
8
OrbiMed
New York
$19.8M -$5.12M -391,302 -20%
Vanguard Group
9
Vanguard Group
Pennsylvania
$17.6M +$900K +68,811 +5%
LCM
10
Laurion Capital Management
New York
$17.4M – – –
ASP
11
Adams Street Partners
Illinois
$13.9M -$5.27M -402,847 -26%
Millennium Management
12
Millennium Management
New York
$13.6M +$13.1M +1,002,941 +1,016%
Jennison Associates
13
Jennison Associates
New York
$13.3M +$5.04M +385,726 +55%
CP
14
Caligan Partners
New York
$12.4M +$392K +30,000 +3%
IHAM
15
Integral Health Asset Management
New York
$10.8M +$6.79M +519,000 +146%
American Century Companies
16
American Century Companies
Missouri
$10.4M -$1.09M -83,020 -9%
ACM
17
ADAR1 Capital Management
Texas
$10.4M +$1.47M +112,140 +15%
BFM
18
Boothbay Fund Management
New York
$8M +$576K +44,067 +7%
NCM
19
Nantahala Capital Management
Connecticut
$7.79M – – –
Geode Capital Management
20
Geode Capital Management
Massachusetts
$7.63M -$10.7K -820 -0.1%
Morgan Stanley
21
Morgan Stanley
New York
$7.26M +$963K +73,631 +14%
State Street
22
State Street
Massachusetts
$6.21M +$272K +20,767 +4%
JP Morgan Chase
23
JP Morgan Chase
New York
$6.2M +$6.3M +482,174 +2,251%
SC
24
Stempoint Capital
New York
$4.93M +$5.23M +400,101 New
SAM
25
Sectoral Asset Management
Quebec, Canada
$4.69M +$672K +51,370 +16%
1
2 3 4 5

MLYS Hedge Fund Activity: Q4 2024 in Review

108 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q4 2024, worth a combined $572M — up 6% from $540M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new MLYS positions and 14 closed out — a net gain of 2 holders — while 44 added to existing stakes and 17 trimmed.

The largest buyer was Millennium Management, adding an estimated $13.1M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.27M sold.

  • 108 institutional investors held Mineralys Therapeutics (MLYS) as of Q4 2024, up from 106 in Q3 2024.
  • Funds reported $572M of Mineralys Therapeutics stock for Q4 2024, up 6% quarter-over-quarter.
  • 16 funds opened new Mineralys Therapeutics positions in Q4 2024 and 14 closed out, a net change of +2 holders.
  • The largest Mineralys Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $13.1M added.
  • The largest Mineralys Therapeutics seller in Q4 2024 was Octagon Capital Advisors, an estimated $7.27M sold.

Based on aggregated 13F filings for Q4 2024.